头颈部非转移性肿瘤放疗后健康效用与症状趋势
该研究纳入1851例接受根治性、术后放疗或放化疗的头颈部肿瘤患者,采用EQ-5D-3L、EQ-VAS、EORTC QLQ-C30和QLQ-H&N35及CTCAE v4.0纵向评估放疗后健康相关生活质量与毒性负担;结果显示健康效用放疗期间下降、12个月内恢复至基线以上并稳定至60个月,口干和黏唾液长期持续,3级口干、吞咽困难和咽喉疼痛分别与效用下降-0.051、-0.062和-0.106相关。
要点
- 放疗期间健康效用下降,12个月内恢复至基线以上并稳定至60个月。
- 口干和黏唾液症状持续至长期随访。
- 3级咽喉疼痛、吞咽困难和口干与效用下降相关。
核心结论
- 口干、咽喉疼痛、口腔疼痛和吞咽困难显著影响EQ-5D效用值,且症状可持续至治疗后五年。
研究设计与样本
- 单中心纳入2007年3月至2022年9月在格罗宁根大学医学中心接受根治性、术后放疗或放化疗的1851例头颈部肿瘤患者。
- 采用EQ-5D-3L和EQ-VAS评估健康状态与效用,EORTC QLQ-C30和QLQ-H&N35评估患者报告结局,CTCAE v4.0和UMCG吞咽困难量表由医生评定毒性。
- 评估时间点为放疗前、放疗后12周及6、12、18、24、30、36、48和60个月,采用广义估计方程(GEE)分析健康效用值。
主要发现
- 健康相关生活质量在放疗期间下降,第一年内部分恢复,并稳定至60个月。
- 模型估计的EQ-5D效用值在治疗期间下降,至12个月时恢复至基线以上水平。
- 口干和黏唾液症状在长期随访中持续存在。
- 多变量GEE模型中,CTCAE 3级口干和吞咽困难分别与效用下降-0.051和-0.062相关,3级咽喉疼痛下降幅度最大(-0.106)。
- 医生评定的毒性严重程度增加与效用损失增大持续相关。
关键数值与推荐
- CTCAE 3级口干与EQ-5D效用下降-0.051相关。
- CTCAE 3级吞咽困难与EQ-5D效用下降-0.062相关。
- CTCAE 3级咽喉疼痛与EQ-5D效用下降-0.106相关。
临床怎么用
- 可利用上述效用损失数据支持基于QALY的健康经济评估。
- 针对口干、咽喉疼痛、口腔疼痛和吞咽困难等关键毒性进行干预,可能改善患者健康相关生活质量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This study characterizes longitudinal changes in health-related quality of life (HRQoL) following radiotherapy in patients with head and neck cancer (HNC) and quantifies associated toxicity burden to inform future health technology assessments (HTA). MATERIALS AND METHODS: HNC patients receiving definitive, postoperative radiotherapy, or chemoradiation at the University Medical Center Groningen from March 2007 to September 2022 were included. Health status and utility were assessed using EQ-5D-3 L and EQ-VAS, while patient-reported HRQoL and symptom burden were evaluated with EORTC QLQ-C30 and QLQ-H&N35. Toxicities were rated by physicians using CTCAE v4.0 and the UMCG dysphagia scale. Assessments were conducted before radiotherapy, at 12 weeks, and 6, 12, 18, 24, 30, 36, 48, and 60 months post-treatment. Generalized Estimating Equations (GEE) analyzed health utility values. RESULTS: Among 1,851 patients, HRQoL declined during radiotherapy and partially recovered within the first year, remaining stable up to 60 months. Model-estimated EQ-5D utility decreased during treatment and recovered to above baseline levels by 12 months. Dry mouth and sticky saliva persisted at long-term follow-up. In multivariable GEE models, CTCAE Grade 3 xerostomia and dysphagia were associated with utility decrements of -0.051 and -0.062, respectively, while grade 3 pharyngolaryngeal pain showed the largest reduction (-0.106). Increasing physician-rated toxicity severity was consistently associated with greater disutility. CONCLUSION: Xerostomia, pharyngolaryngeal pain, oral pain, , and dysphagia significantly impacted EQ-5D-derived utility values. Disutility increased with higher CTCAE-rated toxicities. Symptoms persisted for up to five years post-treatment. These findings can inform QALY-based health economic evaluations and suggest interventions targeting key toxicities to improve patient HRQoL.
引用
- Larrotta-Castillo D, Chen YH, van der Hoek L, et al. Post-radiotherapy health utility and symptom trends in patients with non-metastatic head and neck cancer. Radiother Oncol. 2026. PMID: 41812861. doi:10.1016/j.radonc.2026.111473
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。